Relationship between Changes in Plasma Leptin Concentrations and Plasminogen Activator Inhibitor-1 in Obese Prepubertal Children after Nine Months of TreatmentValle Jiménez M.a · Martos R.b · Morales R.M.a · Valle R.c · Cañete M.D.d · Urbano M.M.a · Bermudo F.a · Cañete R.e
aClinical Laboratory Department, Valle de los Pedroches Hospital, and bHealth Center of Pozoblanco, Pozoblanco, cSchool of Medicine and dGrupo PAIDI CTS-329 (IMIBIC), Universidad de Córdoba, and ePediatric Department, Reina Sofía Hospital, Córdoba, Spain
Background/Aims: The metabolic syndrome (MS) is associated with insulin resistance (IR), inappropriate fibrinolysis and high plasma leptin concentrations. The aim of this study was to quantify fibrinolysis and MS-related variables in obese prepubertal children and to evaluate changes in these variables as a result of improved body mass index (BMI), IR and leptin levels following 9 months of treatment. Methods: The homeostasis model assessment for insulin resistance (HOMA-IR), leptin, plasminogen activator inhibitor-1 (PAI-1) and lipid profile were studied at baseline in obese (n = 50) and nonobese children (n = 50), and after 9 months of treatment in obese children. Results: In the cross-sectional study the mean values for insulin, HOMA-IR, triglycerides, leptin and PAI-1 were significantly higher in obese children than in controls. High-density lipoprotein cholesterol (HDLc) and apolipoprotein A-1 were significantly lower. In the longitudinal study, after 9 months, children with lowered BMI standard deviation score displayed a significant decrease in insulin, HOMA-IR, PAI-1, leptin and triglyceride levels, and an increase in HDLc. Only leptin proved to be an independent predictive factor for changes in PAI-1 (p = 0.010). Conclusion: Obesity-linked disorders appear in obese children prior to puberty; these disorders can be improved by decreasing BMI. Changes in leptin levels were found to independently predict changes in PAI-1 in obese children and can help to diagnose complications associated with the obesity.
© 2013 S. Karger AG, Basel